A bipartisan bill introduced in the Senate this week aims to address the growing issue of drug shortages.
A bipartisan bill introduced in the Senate this week aims to address the growing issue of drug shortages.
Introduced by Senators Susan Collins, R-Maine, and Tina Smith, D-Minnesota, the Mitigating Emergency Drug Shortages (MEDS) Act would give the FDA increased authority and expand manufacturing reporting requirements.
The bill was introduced the same day the FDA released the results of a task force, which spent about a year probing the causes of drug shortages as well as proposing some solutions. The report called the pharmaceutical marketplace “broken” and said that manufacturers need financial incentives to produce drugs at risk for shortage.
According to a statement from Collins’ office, the bill would:
The MEDS Act is supported by Premier, the American Hospital Association, the American Society of Anesthesiologists, the American Society of Clinical Oncology, the American Society of Health-Systems Pharmacists, and the Institute for Safe Medication Practices.
There were more than 200 shortages in 2018, the organizations said, and “The MEDS Act is a thoughtful, holistic and sustainable approach to eliminating drugs shortages,” said Blair Childs, senior vice president of public affairs of Premier, in a statement.
Collins’ office said drug shortages add $230 million a year to US drug costs and $216 million a year in increased labor costs as healthcare providers scramble to find an alternative source of medication.
CHMP Pushes 3 Biosimilars Forward, Spelling Hope for Ophthalmology, Supportive Care Markets
February 6th 2025The European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) recommended 3 biosimilars and new indications for reference biologics, moving them closer to final European approval and expanding patient access.
Biosimilars Policy Roundup for September 2024—Podcast Edition
October 6th 2024On this episode of Not So Different, we discuss the FDA's approval of a new biosimilar for treating retinal conditions, which took place in September 2024 alongside other major industry developments, including ongoing legal disputes and broader trends in market dynamics and regulatory challenges.
BioRationality: No More Biosimilars—Just Biogenerics
February 3rd 2025Sarfaraz K. Niazi, PhD, argues that regulatory agencies should eliminate redundant clinical efficacy testing for biosimilars, recognizing them as "biogenerics" since physicochemical and in vitro biological comparisons are sufficient to ensure safety and efficacy.
FTC Releases Second Report on PBMs Meddling in Generic Drug Markets
January 19th 2025The 3 largest pharmacy benefit managers (PBMs) increased many specialty generic drugs prices by hundreds of percent, with some drugs seeing thousands of percent markups, according to the Federal Trade Commission (FTC)’s second interim report on PBM practices.
Improving Biosimilar Access Through Global Regulatory Convergence
January 15th 2025Achieving global regulatory harmonization for biosimilar vaccines and immunotherapies is essential to improving market access, reducing costs, and enhancing patient outcomes by streamlining approval processes, fostering international collaboration, and addressing regulatory disparities.